Medtronic's MiniMed 780G Automated Insulin Delivery System Named One of Fast Company’s 'World Changing Ideas'

Medtronic's MiniMed 780G Automated Insulin Delivery System

Fast Company, a business magazine headquartered in New York, named Medtronic's MiniMed 780G automated insulin delivery system as one of the top ideas transforming the world in North America. This marks the fourth consecutive year that Medtronic’s technology has been featured on the annual list, which recognizes companies and products addressing "the most pressing issues of our time."

Fast Company's 2024 World Changing Ideas Awards named 12 finalists in the North America categories, including the MiniMed 780G system.

Que Dallara, Executive Vice President and President of Medtronic Diabetes, said: "The MiniMed 780G system being recognized as an idea that changes the world reflects our commitment to simplifying diabetes care and alleviating the mental burden of this relentless disease. We are honored to receive this recognition and will continue our relentless efforts to provide individuals with the technology needed for those with type 1 diabetes to thrive."

"Diabetes is a highly individualized condition, and no two journeys are the same. The MiniMed 780G system is designed to adapt to each person's unique needs and goals to help alleviate the burden of diabetes management, allowing individuals with diabetes to spend more time doing what they love."

The U.S. Food and Drug Administration (FDA) approved the MiniMed 790G device in April 2023 for individuals with type 1 diabetes aged 7 years and older. A new feature of the pump is meal detection technology, which can deliver insulin during moments when users forget or underestimate how a meal may impact their health. According to Medtronic, this feature brings diabetes technology "one step closer to mimicking a healthy pancreas."

The FDA approval was partially based on clinical data first shared with the public in June 2020. Researchers found that real-world study data from the MiniMed 780G showed that over 100,000 individuals with Type 1 diabetes achieved 78.8% Time in Range (TIR) by using the recommended optimal settings, surpassing the international goal of 70% TIR.

The Medtronic MiniMed™ 780G system is the latest HCL insulin pump system. It received EU CE approval in June 2020 for use in T1DM patients aged 7 to 80 and has not yet been approved by the U.S. FDA. The system includes the 780G pump, the third- and fourth-generation Medtronic small seashell (Guardian™ Sensor 3, 4) continuous glucose monitoring (CGM), and an automated insulin adjustment algorithm. The SmartGuard™ technology based on the IPD+IFB algorithm, which is integrated into the 780G system, ensures subtle automatic dose calibration every 5 minutes when high or low blood glucose trends occur, helping patients avoid hyperglycemia or hypoglycemia. The system can adjust blood glucose targets as low as 5.5 mmol/L, lower than the 6.7 mmol/L of the 670G.

01

CGM Guardian™ Sensor 3：Blood glucose is measured once every 5 minutes, totaling 288 times throughout the day, and this information is automatically sent to the insulin pump to view blood glucose levels and trend direction.

02

MiniMed™ Mio™ Advanced Infusion Set:Its features are simplicity, speed, and worry-free operation. The infusion device is designed with a preloaded insertion mechanism, allowing for fewer steps, faster, and easier replacement. Additionally, it can be inserted with just one hand, assisting patients to effortlessly place the infusion set in hard-to-reach areas.

03

Insulin Pump:Based on the latest blood glucose information received from the CGM every 5 minutes, the waterproof pump automatically adjusts and corrects insulin delivery. If the blood glucose trend rises, the pump provides more insulin to the patient. If the blood glucose trend decreases, it reduces the insulin provided.

04

APP for smartphones or watches:Can display in real time active insulin, TIR, average blood glucose, insulin dosage during this period, blood glucose trend, etc.

This Issue's Planning: Shen Li

Editorial Responsibility: Chen Baolin

Author of this article: Yun Ye Xuan

Post-production:Ling Wujuan